PROT# CLTR0308-205: Phase IIB, Multicenter, Randomized, Open-Label Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Intersive Salvage Therapy in Adult Patients (equal or over)60 Years Old with AML in First Relapse Following an Initial

Project: Research project

Project Details

StatusFinished
Effective start/end date7/6/09 → 7/6/12

Funding

  • Celator Pharmaceuticals, Inc. (CLTR0308-205)